VB-111: Phase I/II data

An open-label, dose-escalation, U.S. Phase I/II trial in 21 patients with recurrent platinum-resistant ovarian cancer

Read the full 151 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE